探索适应性健康技术评估,以评估10种癌症干预措施:来自印度试点研究的见解和教训
Srobana Ghosh1, C S Pramesh2, Manju Sengar2
1Center for Global Development, London, UK srobana.ghosh@gmail.com.
BMJ evidence-based medicine
|January 2, 2025
概括
适应性卫生技术评估 (aHTA) 方法被证明是可行的,用于评估在资源有限的环境中癌症干预措施. 这种方法有效地利用国际证据来决定成本效益.
科学领域:
- 卫生经济学 卫生经济学
- 在瘤学瘤学.
- 卫生技术评估 卫生技术评估
背景情况:
- 卫生技术评估 (HTA) 对医疗保健资源分配至关重要,但往往资源密集.
- 通过利用国际证据来调整HTA为资源有限的环境提供了务实的解决方案.
研究的目的:
- 试验一种适应性HTA (aHTA) 方法,用于评估十种癌症干预措施.
- 在资源有限的环境中评估HTA的可行性和实用性.
主要方法:
- 一个由临床医生和卫生经济学家组成的合作工作组成立.
- 对十项癌症干预措施进行了国际HTA报告和经济评估的快速审查.
- 提取和分析了成本效益,价格比较,治疗成本和国家保险影响的数据.
主要成果:
- 在10项干预中,有9项有足够的证据来确定成本效益.
- 三项干预措施具有潜在的成本效益,其中两项通过价格调整实现了这一地位.
- 公开可用的证据提供了有关成本效益,益处和治疗成本的一致信息.
结论:
- 适应性HTA (aHTA) 方法是传统HTA的可行,资源敏感的替代方案.
- 当国际成本效益数据可用时,aHTA有效地为资源有限的环境中的决策提供信息.
相关概念视频
01:21Cancer Survival Analysis
290
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
290
01:29Issues And Trends In Healthcare Delivery System
5.5K
The issues and trends in healthcare delivery are constantly changing. The COVID-19 pandemic is one recent issue that wreaked havoc on healthcare systems, causing a shortage of healthcare workers, high demand for medicines and supplies, and increased medical expenditure due to a lack of insurance. Other issues include rising healthcare costs and care fragmentation.
Cost Containment
Payment for healthcare services has historically promoted adoption of costly and often unnecessary or inefficient...
Cost Containment
Payment for healthcare services has historically promoted adoption of costly and often unnecessary or inefficient...
5.5K
01:30Cancer Vaccines
237
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
237
01:27Tumor Immunotherapy
394
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
394
02:50Combination Therapies and Personalized Medicine
4.7K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.7K
01:12Hazard Ratio
62
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
62